See more : Banque Cantonale Vaudoise (BQCNF) Income Statement Analysis – Financial Results
Complete financial analysis of Nuformix plc (NFX.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nuformix plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Pilbara Minerals Limited (PILBF) Income Statement Analysis – Financial Results
- Un Monde International Ltd. (ARMC) Income Statement Analysis – Financial Results
- Rhinomed Limited (RNO.AX) Income Statement Analysis – Financial Results
- Simcere Pharmaceutical Group Limited (2096.HK) Income Statement Analysis – Financial Results
- Nexi S.p.A. (NEXI.MI) Income Statement Analysis – Financial Results
Nuformix plc (NFX.L)
About Nuformix plc
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
| Metric | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 50.00K | 195.55K | 535.00K | 610.00K | 15.00K | 0.00 | 607.50K | 174.00K | 183.86K |
| Cost of Revenue | 36.75K | 38.67K | 108.83K | 333.60K | 537.53K | 203.87K | 86.19K | 71.85K | 66.07K | 39.08K |
| Gross Profit | -36.75K | 11.33K | 86.72K | 201.41K | 72.47K | -188.87K | -86.19K | 535.65K | 107.94K | 144.78K |
| Gross Profit Ratio | 0.00% | 22.66% | 44.35% | 37.65% | 11.88% | -1,259.12% | 0.00% | 88.17% | 62.03% | 78.74% |
| Research & Development | 163.40K | 572.92K | 362.88K | 524.98K | 1.45M | 876.58K | 472.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 618.65K | 1.32K | 1.51K | 1.12K | 911.68K | 729.02K | 685.06K | 327.59K | 489.90K | 55.35K |
| Selling & Marketing | 0.00 | 707.36K | 1.10M | 593.48K | 0.00 | 0.00 | 0.00 | 22.83K | 0.00 | 0.00 |
| SG&A | 618.65K | 708.68K | 1.10M | 594.60K | 911.68K | 729.02K | 685.06K | 350.42K | 489.90K | 55.35K |
| Other Expenses | -163.40K | 0.00 | 0.00 | 0.00 | 823.80K | 683.62K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 618.65K | 1.28M | 1.46M | 1.12M | 1.74M | 1.41M | 685.06K | 350.42K | 330.27K | 139.19K |
| Cost & Expenses | 618.65K | 1.32M | 1.57M | 1.45M | 2.27M | 1.62M | 685.06K | 350.42K | 396.33K | 178.27K |
| Interest Income | 0.00 | 0.00 | 3.05 | 15.30 | 28.41 | 0.00 | 0.00 | 0.00 | 1.59 | 2.78 |
| Interest Expense | 0.00 | 0.00 | 3.05K | 15.30K | 28.41K | 11.06K | 1.77K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 36.75K | 36.98K | 93.05K | 81.69K | 52.82K | 47.43K | 35.03K | 26.23K | 36.69K | 15.32K |
| EBITDA | -581.90K | -1.23M | -1.28M | -832.90K | -1.76M | -1.91M | -298.96K | 288.10K | -185.64K | 299.28K |
| EBITDA Ratio | 0.00% | -2,466.58% | -655.04% | -156.36% | -264.59% | -10,310.39% | 0.00% | -57.68% | -106.69% | 162.78% |
| Operating Income | -618.65K | -1.27M | -1.37M | -918.18K | -1.81M | -1.96M | -685.06K | -350.42K | -222.33K | 283.97K |
| Operating Income Ratio | 0.00% | -2,540.54% | -702.62% | -171.62% | -296.81% | -13,076.71% | 0.00% | -57.68% | -127.78% | 154.45% |
| Total Other Income/Expenses | 0.00 | 0.00 | -3.05K | -15.84K | -32.21K | -3.55K | -21.36K | 0.00 | -1.59K | -2.78K |
| Income Before Tax | -618.65K | -1.27M | -1.38M | -929.88K | -1.84M | -1.97M | -685.06K | -350.42K | -223.93K | 281.19K |
| Income Before Tax Ratio | 0.00% | -2,540.54% | -703.52% | -173.81% | -302.09% | -13,100.35% | 0.00% | -57.68% | -128.69% | 152.94% |
| Income Tax Expense | -45.67K | -161.28K | -122.24K | -173.51K | -181.50K | -126.79K | -68.44K | 4.33K | 19.76K | 1.65K |
| Net Income | -572.98K | -1.11M | -1.25M | -756.38K | -1.66M | -1.84M | -685.06K | -350.42K | -204.16K | 279.54K |
| Net Income Ratio | 0.00% | -2,217.99% | -641.01% | -141.38% | -272.33% | -12,255.09% | 0.00% | -57.68% | -117.33% | 152.04% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 719.46M | 598.45M | 580.63M | 477.06M | 460.75M | 373.55M | 95.75M | 60.09M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 719.46M | 598.45M | 580.63M | 477.06M | 460.75M | 373.55M | 95.75M | 60.09M | 0.00 | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports